2,667 codes
Unacceptable principal diagnosis codes
Codes that describe a circumstance influencing health status rather than a current illness, so they are unacceptable as the principal diagnosis for an inpatient stay. Source: Medicare Code Editor (MCE) v44, effective October 1, 2026.
Chapter 19: Injury, poisoning and certain other consequences of external causes
- S06.A0XATraumatic brain compression without herniation, initial encounter
- S06.A0XDTraumatic brain compression without herniation, subsequent encounter
- S06.A0XSTraumatic brain compression without herniation, sequela
- S06.A1XATraumatic brain compression with herniation, initial encounter
- S06.A1XDTraumatic brain compression with herniation, subsequent encounter
- S06.A1XSTraumatic brain compression with herniation, sequela
- T36.0X5AAdverse effect of penicillins, initial encounter
- T36.0X5DAdverse effect of penicillins, subsequent encounter
- T36.0X5SAdverse effect of penicillins, sequela
- T36.0X6AUnderdosing of penicillins, initial encounter
- T36.0X6DUnderdosing of penicillins, subsequent encounter
- T36.0X6SUnderdosing of penicillins, sequela
- T36.1X5AAdverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
- T36.1X5DAdverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter
- T36.1X5SAdverse effect of cephalosporins and other beta-lactam antibiotics, sequela
- T36.1X6AUnderdosing of cephalosporins and other beta-lactam antibiotics, initial encounter
- T36.1X6DUnderdosing of cephalosporins and other beta-lactam antibiotics, subsequent encounter
- T36.1X6SUnderdosing of cephalosporins and other beta-lactam antibiotics, sequela
- T36.2X5AAdverse effect of chloramphenicol group, initial encounter
- T36.2X5DAdverse effect of chloramphenicol group, subsequent encounter
- T36.2X5SAdverse effect of chloramphenicol group, sequela
- T36.2X6AUnderdosing of chloramphenicol group, initial encounter
- T36.2X6DUnderdosing of chloramphenicol group, subsequent encounter
- T36.2X6SUnderdosing of chloramphenicol group, sequela
- T36.3X5AAdverse effect of macrolides, initial encounter
- T36.3X5DAdverse effect of macrolides, subsequent encounter
- T36.3X5SAdverse effect of macrolides, sequela
- T36.3X6AUnderdosing of macrolides, initial encounter
- T36.3X6DUnderdosing of macrolides, subsequent encounter
- T36.3X6SUnderdosing of macrolides, sequela
- T36.4X5AAdverse effect of tetracyclines, initial encounter
- T36.4X5DAdverse effect of tetracyclines, subsequent encounter
- T36.4X5SAdverse effect of tetracyclines, sequela
- T36.4X6AUnderdosing of tetracyclines, initial encounter
- T36.4X6DUnderdosing of tetracyclines, subsequent encounter
- T36.4X6SUnderdosing of tetracyclines, sequela
- T36.5X5AAdverse effect of aminoglycosides, initial encounter
- T36.5X5DAdverse effect of aminoglycosides, subsequent encounter
- T36.5X5SAdverse effect of aminoglycosides, sequela
- T36.5X6AUnderdosing of aminoglycosides, initial encounter
- T36.5X6DUnderdosing of aminoglycosides, subsequent encounter
- T36.5X6SUnderdosing of aminoglycosides, sequela
- T36.6X5AAdverse effect of rifampicins, initial encounter
- T36.6X5DAdverse effect of rifampicins, subsequent encounter
- T36.6X5SAdverse effect of rifampicins, sequela
- T36.6X6AUnderdosing of rifampicins, initial encounter
- T36.6X6DUnderdosing of rifampicins, subsequent encounter
- T36.6X6SUnderdosing of rifampicins, sequela
- T36.7X5AAdverse effect of antifungal antibiotics, systemically used, initial encounter
- T36.7X5DAdverse effect of antifungal antibiotics, systemically used, subsequent encounter
- T36.7X5SAdverse effect of antifungal antibiotics, systemically used, sequela
- T36.7X6AUnderdosing of antifungal antibiotics, systemically used, initial encounter
- T36.7X6DUnderdosing of antifungal antibiotics, systemically used, subsequent encounter
- T36.7X6SUnderdosing of antifungal antibiotics, systemically used, sequela
- T36.8X5AAdverse effect of other systemic antibiotics, initial encounter
- T36.8X5DAdverse effect of other systemic antibiotics, subsequent encounter
- T36.8X5SAdverse effect of other systemic antibiotics, sequela
- T36.8X6AUnderdosing of other systemic antibiotics, initial encounter
- T36.8X6DUnderdosing of other systemic antibiotics, subsequent encounter
- T36.8X6SUnderdosing of other systemic antibiotics, sequela
- T36.95XAAdverse effect of unspecified systemic antibiotic, initial encounter
- T36.95XDAdverse effect of unspecified systemic antibiotic, subsequent encounter
- T36.95XSAdverse effect of unspecified systemic antibiotic, sequela
- T36.96XAUnderdosing of unspecified systemic antibiotic, initial encounter
- T36.96XDUnderdosing of unspecified systemic antibiotic, subsequent encounter
- T36.96XSUnderdosing of unspecified systemic antibiotic, sequela
- T36.AX5AAdverse effect of fluoroquinolone antibiotics, initial encounter
- T36.AX5DAdverse effect of fluoroquinolone antibiotics, subsequent encounter
- T36.AX5SAdverse effect of fluoroquinolone antibiotics, sequela
- T36.AX6AUnderdosing of fluoroquinolone antibiotics, initial encounter
- T36.AX6DUnderdosing of fluoroquinolone antibiotics, subsequent encounter
- T36.AX6SUnderdosing of fluoroquinolone antibiotics, sequela
- T37.0X5AAdverse effect of sulfonamides, initial encounter
- T37.0X5DAdverse effect of sulfonamides, subsequent encounter
- T37.0X5SAdverse effect of sulfonamides, sequela
- T37.0X6AUnderdosing of sulfonamides, initial encounter
- T37.0X6DUnderdosing of sulfonamides, subsequent encounter
- T37.0X6SUnderdosing of sulfonamides, sequela
- T37.1X5AAdverse effect of antimycobacterial drugs, initial encounter
- T37.1X5DAdverse effect of antimycobacterial drugs, subsequent encounter
- T37.1X5SAdverse effect of antimycobacterial drugs, sequela
- T37.1X6AUnderdosing of antimycobacterial drugs, initial encounter
- T37.1X6DUnderdosing of antimycobacterial drugs, subsequent encounter
- T37.1X6SUnderdosing of antimycobacterial drugs, sequela
- T37.2X5AAdverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
- T37.2X5DAdverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter
- T37.2X5SAdverse effect of antimalarials and drugs acting on other blood protozoa, sequela
- T37.2X6AUnderdosing of antimalarials and drugs acting on other blood protozoa, initial encounter
- T37.2X6DUnderdosing of antimalarials and drugs acting on other blood protozoa, subsequent encounter
- T37.2X6SUnderdosing of antimalarials and drugs acting on other blood protozoa, sequela
- T37.3X5AAdverse effect of other antiprotozoal drugs, initial encounter
- T37.3X5DAdverse effect of other antiprotozoal drugs, subsequent encounter
- T37.3X5SAdverse effect of other antiprotozoal drugs, sequela
- T37.3X6AUnderdosing of other antiprotozoal drugs, initial encounter
- T37.3X6DUnderdosing of other antiprotozoal drugs, subsequent encounter
- T37.3X6SUnderdosing of other antiprotozoal drugs, sequela
- T37.4X5AAdverse effect of anthelminthics, initial encounter
- T37.4X5DAdverse effect of anthelminthics, subsequent encounter
- T37.4X5SAdverse effect of anthelminthics, sequela
- T37.4X6AUnderdosing of anthelminthics, initial encounter
- T37.4X6DUnderdosing of anthelminthics, subsequent encounter
- T37.4X6SUnderdosing of anthelminthics, sequela
- T37.5X5AAdverse effect of antiviral drugs, initial encounter
- T37.5X5DAdverse effect of antiviral drugs, subsequent encounter
- T37.5X5SAdverse effect of antiviral drugs, sequela
- T37.5X6AUnderdosing of antiviral drugs, initial encounter
- T37.5X6DUnderdosing of antiviral drugs, subsequent encounter
- T37.5X6SUnderdosing of antiviral drugs, sequela
- T37.8X5AAdverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
- T37.8X5DAdverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter
- T37.8X5SAdverse effect of other specified systemic anti-infectives and antiparasitics, sequela
- T37.8X6AUnderdosing of other specified systemic anti-infectives and antiparasitics, initial encounter
- T37.8X6DUnderdosing of other specified systemic anti-infectives and antiparasitics, subsequent encounter
- T37.8X6SUnderdosing of other specified systemic anti-infectives and antiparasitics, sequela
- T37.95XAAdverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
- T37.95XDAdverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter
- T37.95XSAdverse effect of unspecified systemic anti-infective and antiparasitic, sequela
- T37.96XAUnderdosing of unspecified systemic anti-infectives and antiparasitics, initial encounter
- T37.96XDUnderdosing of unspecified systemic anti-infectives and antiparasitics, subsequent encounter
- T37.96XSUnderdosing of unspecified systemic anti-infectives and antiparasitics, sequela
- T38.0X5AAdverse effect of glucocorticoids and synthetic analogues, initial encounter
- T38.0X5DAdverse effect of glucocorticoids and synthetic analogues, subsequent encounter
- T38.0X5SAdverse effect of glucocorticoids and synthetic analogues, sequela
- T38.0X6AUnderdosing of glucocorticoids and synthetic analogues, initial encounter
- T38.0X6DUnderdosing of glucocorticoids and synthetic analogues, subsequent encounter
- T38.0X6SUnderdosing of glucocorticoids and synthetic analogues, sequela
- T38.1X5AAdverse effect of thyroid hormones and substitutes, initial encounter
- T38.1X5DAdverse effect of thyroid hormones and substitutes, subsequent encounter
- T38.1X5SAdverse effect of thyroid hormones and substitutes, sequela
- T38.1X6AUnderdosing of thyroid hormones and substitutes, initial encounter
- T38.1X6DUnderdosing of thyroid hormones and substitutes, subsequent encounter
- T38.1X6SUnderdosing of thyroid hormones and substitutes, sequela
- T38.2X5AAdverse effect of antithyroid drugs, initial encounter
- T38.2X5DAdverse effect of antithyroid drugs, subsequent encounter
- T38.2X5SAdverse effect of antithyroid drugs, sequela
- T38.2X6AUnderdosing of antithyroid drugs, initial encounter
- T38.2X6DUnderdosing of antithyroid drugs, subsequent encounter
- T38.2X6SUnderdosing of antithyroid drugs, sequela
- T38.3X5AAdverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
- T38.3X5DAdverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter
- T38.3X5SAdverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
- T38.3X6AUnderdosing of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
- T38.3X6DUnderdosing of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter
- T38.3X6SUnderdosing of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
- T38.4X5AAdverse effect of oral contraceptives, initial encounter
- T38.4X5DAdverse effect of oral contraceptives, subsequent encounter
- T38.4X5SAdverse effect of oral contraceptives, sequela
- T38.4X6AUnderdosing of oral contraceptives, initial encounter
- T38.4X6DUnderdosing of oral contraceptives, subsequent encounter
- T38.4X6SUnderdosing of oral contraceptives, sequela
- T38.5X5AAdverse effect of other estrogens and progestogens, initial encounter
- T38.5X5DAdverse effect of other estrogens and progestogens, subsequent encounter
- T38.5X5SAdverse effect of other estrogens and progestogens, sequela
- T38.5X6AUnderdosing of other estrogens and progestogens, initial encounter
- T38.5X6DUnderdosing of other estrogens and progestogens, subsequent encounter
- T38.5X6SUnderdosing of other estrogens and progestogens, sequela
- T38.6X5AAdverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
- T38.6X5DAdverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter
- T38.6X5SAdverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
- T38.6X6AUnderdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
- T38.6X6DUnderdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter
- T38.6X6SUnderdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
- T38.7X5AAdverse effect of androgens and anabolic congeners, initial encounter
- T38.7X5DAdverse effect of androgens and anabolic congeners, subsequent encounter
- T38.7X5SAdverse effect of androgens and anabolic congeners, sequela
- T38.7X6AUnderdosing of androgens and anabolic congeners, initial encounter
- T38.7X6DUnderdosing of androgens and anabolic congeners, subsequent encounter
- T38.7X6SUnderdosing of androgens and anabolic congeners, sequela
- T38.805AAdverse effect of unspecified hormones and synthetic substitutes, initial encounter
- T38.805DAdverse effect of unspecified hormones and synthetic substitutes, subsequent encounter
- T38.805SAdverse effect of unspecified hormones and synthetic substitutes, sequela
- T38.806AUnderdosing of unspecified hormones and synthetic substitutes, initial encounter
- T38.806DUnderdosing of unspecified hormones and synthetic substitutes, subsequent encounter
- T38.806SUnderdosing of unspecified hormones and synthetic substitutes, sequela
- T38.815AAdverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
- T38.815DAdverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter
- T38.815SAdverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
- T38.816AUnderdosing of anterior pituitary [adenohypophyseal] hormones, initial encounter
- T38.816DUnderdosing of anterior pituitary [adenohypophyseal] hormones, subsequent encounter
- T38.816SUnderdosing of anterior pituitary [adenohypophyseal] hormones, sequela
- T38.895AAdverse effect of other hormones and synthetic substitutes, initial encounter
- T38.895DAdverse effect of other hormones and synthetic substitutes, subsequent encounter
- T38.895SAdverse effect of other hormones and synthetic substitutes, sequela
- T38.896AUnderdosing of other hormones and synthetic substitutes, initial encounter
- T38.896DUnderdosing of other hormones and synthetic substitutes, subsequent encounter
- T38.896SUnderdosing of other hormones and synthetic substitutes, sequela
- T38.905AAdverse effect of unspecified hormone antagonists, initial encounter
- T38.905DAdverse effect of unspecified hormone antagonists, subsequent encounter
- T38.905SAdverse effect of unspecified hormone antagonists, sequela
- T38.906AUnderdosing of unspecified hormone antagonists, initial encounter
- T38.906DUnderdosing of unspecified hormone antagonists, subsequent encounter
- T38.906SUnderdosing of unspecified hormone antagonists, sequela
- T38.995AAdverse effect of other hormone antagonists, initial encounter
- T38.995DAdverse effect of other hormone antagonists, subsequent encounter
- T38.995SAdverse effect of other hormone antagonists, sequela
- T38.996AUnderdosing of other hormone antagonists, initial encounter
- T38.996DUnderdosing of other hormone antagonists, subsequent encounter
- T38.996SUnderdosing of other hormone antagonists, sequela
- T39.015AAdverse effect of aspirin, initial encounter
- T39.015DAdverse effect of aspirin, subsequent encounter
- T39.015SAdverse effect of aspirin, sequela
- T39.016AUnderdosing of aspirin, initial encounter
- T39.016DUnderdosing of aspirin, subsequent encounter
- T39.016SUnderdosing of aspirin, sequela
- T39.095AAdverse effect of salicylates, initial encounter
- T39.095DAdverse effect of salicylates, subsequent encounter
- T39.095SAdverse effect of salicylates, sequela
- T39.096AUnderdosing of salicylates, initial encounter
- T39.096DUnderdosing of salicylates, subsequent encounter
- T39.096SUnderdosing of salicylates, sequela
- T39.1X5AAdverse effect of 4-Aminophenol derivatives, initial encounter
- T39.1X5DAdverse effect of 4-Aminophenol derivatives, subsequent encounter
- T39.1X5SAdverse effect of 4-Aminophenol derivatives, sequela
- T39.1X6AUnderdosing of 4-Aminophenol derivatives, initial encounter
- T39.1X6DUnderdosing of 4-Aminophenol derivatives, subsequent encounter
- T39.1X6SUnderdosing of 4-Aminophenol derivatives, sequela
- T39.2X5AAdverse effect of pyrazolone derivatives, initial encounter
- T39.2X5DAdverse effect of pyrazolone derivatives, subsequent encounter
- T39.2X5SAdverse effect of pyrazolone derivatives, sequela
- T39.2X6AUnderdosing of pyrazolone derivatives, initial encounter
- T39.2X6DUnderdosing of pyrazolone derivatives, subsequent encounter
- T39.2X6SUnderdosing of pyrazolone derivatives, sequela
- T39.315AAdverse effect of propionic acid derivatives, initial encounter
- T39.315DAdverse effect of propionic acid derivatives, subsequent encounter
- T39.315SAdverse effect of propionic acid derivatives, sequela
- T39.316AUnderdosing of propionic acid derivatives, initial encounter
- T39.316DUnderdosing of propionic acid derivatives, subsequent encounter
- T39.316SUnderdosing of propionic acid derivatives, sequela
- T39.395AAdverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
- T39.395DAdverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
- T39.395SAdverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
- T39.396AUnderdosing of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
- T39.396DUnderdosing of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
- T39.396SUnderdosing of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
- T39.4X5AAdverse effect of antirheumatics, not elsewhere classified, initial encounter
- T39.4X5DAdverse effect of antirheumatics, not elsewhere classified, subsequent encounter
- T39.4X5SAdverse effect of antirheumatics, not elsewhere classified, sequela
- T39.4X6AUnderdosing of antirheumatics, not elsewhere classified, initial encounter
- T39.4X6DUnderdosing of antirheumatics, not elsewhere classified, subsequent encounter
- T39.4X6SUnderdosing of antirheumatics, not elsewhere classified, sequela
- T39.8X5AAdverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
- T39.8X5DAdverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
- T39.8X5SAdverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
- T39.8X6AUnderdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
- T39.8X6DUnderdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
- T39.8X6SUnderdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
- T39.95XAAdverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
- T39.95XDAdverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter
- T39.95XSAdverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela
- T39.96XAUnderdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
- T39.96XDUnderdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter
- T39.96XSUnderdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela
- T40.0X5AAdverse effect of opium, initial encounter
- T40.0X5DAdverse effect of opium, subsequent encounter
- T40.0X5SAdverse effect of opium, sequela
- T40.0X6AUnderdosing of opium, initial encounter
- T40.0X6DUnderdosing of opium, subsequent encounter
- T40.0X6SUnderdosing of opium, sequela
- T40.2X5AAdverse effect of other opioids, initial encounter
- T40.2X5DAdverse effect of other opioids, subsequent encounter
- T40.2X5SAdverse effect of other opioids, sequela
- T40.2X6AUnderdosing of other opioids, initial encounter
- T40.2X6DUnderdosing of other opioids, subsequent encounter
- T40.2X6SUnderdosing of other opioids, sequela
- T40.3X5AAdverse effect of methadone, initial encounter
- T40.3X5DAdverse effect of methadone, subsequent encounter
- T40.3X5SAdverse effect of methadone, sequela
- T40.3X6AUnderdosing of methadone, initial encounter
- T40.3X6DUnderdosing of methadone, subsequent encounter
- T40.3X6SUnderdosing of methadone, sequela
- T40.415AAdverse effect of fentanyl or fentanyl analogs, initial encounter
- T40.415DAdverse effect of fentanyl or fentanyl analogs, subsequent encounter
- T40.415SAdverse effect of fentanyl or fentanyl analogs, sequela
- T40.416AUnderdosing of fentanyl or fentanyl analogs, initial encounter
- T40.416DUnderdosing of fentanyl or fentanyl analogs, subsequent encounter
- T40.416SUnderdosing of fentanyl or fentanyl analogs, sequela
- T40.425AAdverse effect of tramadol, initial encounter
- T40.425DAdverse effect of tramadol, subsequent encounter
- T40.425SAdverse effect of tramadol, sequela
- T40.426AUnderdosing of tramadol, initial encounter
- T40.426DUnderdosing of tramadol, subsequent encounter
- T40.426SUnderdosing of tramadol, sequela
- T40.495AAdverse effect of other synthetic narcotics, initial encounter
- T40.495DAdverse effect of other synthetic narcotics, subsequent encounter
- T40.495SAdverse effect of other synthetic narcotics, sequela
- T40.496AUnderdosing of other synthetic narcotics, initial encounter
- T40.496DUnderdosing of other synthetic narcotics, subsequent encounter
- T40.496SUnderdosing of other synthetic narcotics, sequela
- T40.5X5AAdverse effect of cocaine, initial encounter
- T40.5X5DAdverse effect of cocaine, subsequent encounter
- T40.5X5SAdverse effect of cocaine, sequela
- T40.5X6AUnderdosing of cocaine, initial encounter
- T40.5X6DUnderdosing of cocaine, subsequent encounter
- T40.5X6SUnderdosing of cocaine, sequela
- T40.605AAdverse effect of unspecified narcotics, initial encounter
- T40.605DAdverse effect of unspecified narcotics, subsequent encounter
- T40.605SAdverse effect of unspecified narcotics, sequela
- T40.606AUnderdosing of unspecified narcotics, initial encounter
- T40.606DUnderdosing of unspecified narcotics, subsequent encounter
- T40.606SUnderdosing of unspecified narcotics, sequela
- T40.695AAdverse effect of other narcotics, initial encounter
- T40.695DAdverse effect of other narcotics, subsequent encounter
- T40.695SAdverse effect of other narcotics, sequela
- T40.696AUnderdosing of other narcotics, initial encounter
- T40.696DUnderdosing of other narcotics, subsequent encounter
- T40.696SUnderdosing of other narcotics, sequela
- T40.715AAdverse effect of cannabis, initial encounter
- T40.715DAdverse effect of cannabis, subsequent encounter
- T40.715SAdverse effect of cannabis, sequela
- T40.716AUnderdosing of cannabis, initial encounter
- T40.716DUnderdosing of cannabis, subsequent encounter
- T40.716SUnderdosing of cannabis, sequela
- T40.725AAdverse effect of synthetic cannabinoids, initial encounter
- T40.725DAdverse effect of synthetic cannabinoids, subsequent encounter
- T40.725SAdverse effect of synthetic cannabinoids, sequela
- T40.726AUnderdosing of synthetic cannabinoids, initial encounter
- T40.726DUnderdosing of synthetic cannabinoids, subsequent encounter
- T40.726SUnderdosing of synthetic cannabinoids, sequela
- T40.905AAdverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
- T40.905DAdverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter
- T40.905SAdverse effect of unspecified psychodysleptics [hallucinogens], sequela
- T40.906AUnderdosing of unspecified psychodysleptics [hallucinogens], initial encounter
- T40.906DUnderdosing of unspecified psychodysleptics [hallucinogens], subsequent encounter
- T40.906SUnderdosing of unspecified psychodysleptics [hallucinogens], sequela
- T40.995AAdverse effect of other psychodysleptics [hallucinogens], initial encounter
- T40.995DAdverse effect of other psychodysleptics [hallucinogens], subsequent encounter
- T40.995SAdverse effect of other psychodysleptics [hallucinogens], sequela
- T40.996AUnderdosing of other psychodysleptics [hallucinogens], initial encounter
- T40.996DUnderdosing of other psychodysleptics [hallucinogens], subsequent encounter
- T40.996SUnderdosing of other psychodysleptics [hallucinogens], sequela
- T41.0X5AAdverse effect of inhaled anesthetics, initial encounter
- T41.0X5DAdverse effect of inhaled anesthetics, subsequent encounter
- T41.0X5SAdverse effect of inhaled anesthetics, sequela
- T41.0X6AUnderdosing of inhaled anesthetics, initial encounter
- T41.0X6DUnderdosing of inhaled anesthetics, subsequent encounter
- T41.0X6SUnderdosing of inhaled anesthetics, sequela
- T41.1X5AAdverse effect of intravenous anesthetics, initial encounter
- T41.1X5DAdverse effect of intravenous anesthetics, subsequent encounter
- T41.1X5SAdverse effect of intravenous anesthetics, sequela
- T41.1X6AUnderdosing of intravenous anesthetics, initial encounter
- T41.1X6DUnderdosing of intravenous anesthetics, subsequent encounter
- T41.1X6SUnderdosing of intravenous anesthetics, sequela
- T41.205AAdverse effect of unspecified general anesthetics, initial encounter
- T41.205DAdverse effect of unspecified general anesthetics, subsequent encounter
- T41.205SAdverse effect of unspecified general anesthetics, sequela
- T41.206AUnderdosing of unspecified general anesthetics, initial encounter
- T41.206DUnderdosing of unspecified general anesthetics, subsequent encounter
- T41.206SUnderdosing of unspecified general anesthetics, sequela
- T41.295AAdverse effect of other general anesthetics, initial encounter
- T41.295DAdverse effect of other general anesthetics, subsequent encounter
- T41.295SAdverse effect of other general anesthetics, sequela
- T41.296AUnderdosing of other general anesthetics, initial encounter
- T41.296DUnderdosing of other general anesthetics, subsequent encounter
- T41.296SUnderdosing of other general anesthetics, sequela
- T41.3X5AAdverse effect of local anesthetics, initial encounter
- T41.3X5DAdverse effect of local anesthetics, subsequent encounter
- T41.3X5SAdverse effect of local anesthetics, sequela
- T41.3X6AUnderdosing of local anesthetics, initial encounter
- T41.3X6DUnderdosing of local anesthetics, subsequent encounter
- T41.3X6SUnderdosing of local anesthetics, sequela
- T41.45XAAdverse effect of unspecified anesthetic, initial encounter
- T41.45XDAdverse effect of unspecified anesthetic, subsequent encounter
- T41.45XSAdverse effect of unspecified anesthetic, sequela
- T41.46XAUnderdosing of unspecified anesthetics, initial encounter
- T41.46XDUnderdosing of unspecified anesthetics, subsequent encounter
- T41.46XSUnderdosing of unspecified anesthetics, sequela
- T41.5X5AAdverse effect of therapeutic gases, initial encounter
- T41.5X5DAdverse effect of therapeutic gases, subsequent encounter
- T41.5X5SAdverse effect of therapeutic gases, sequela
- T41.5X6AUnderdosing of therapeutic gases, initial encounter
- T41.5X6DUnderdosing of therapeutic gases, subsequent encounter
- T41.5X6SUnderdosing of therapeutic gases, sequela
- T42.0X5AAdverse effect of hydantoin derivatives, initial encounter
- T42.0X5DAdverse effect of hydantoin derivatives, subsequent encounter
- T42.0X5SAdverse effect of hydantoin derivatives, sequela
- T42.0X6AUnderdosing of hydantoin derivatives, initial encounter
- T42.0X6DUnderdosing of hydantoin derivatives, subsequent encounter
- T42.0X6SUnderdosing of hydantoin derivatives, sequela
- T42.1X5AAdverse effect of iminostilbenes, initial encounter
- T42.1X5DAdverse effect of iminostilbenes, subsequent encounter
- T42.1X5SAdverse effect of iminostilbenes, sequela
- T42.1X6AUnderdosing of iminostilbenes, initial encounter
- T42.1X6DUnderdosing of iminostilbenes, subsequent encounter
- T42.1X6SUnderdosing of iminostilbenes, sequela
- T42.2X5AAdverse effect of succinimides and oxazolidinediones, initial encounter
- T42.2X5DAdverse effect of succinimides and oxazolidinediones, subsequent encounter
- T42.2X5SAdverse effect of succinimides and oxazolidinediones, sequela
- T42.2X6AUnderdosing of succinimides and oxazolidinediones, initial encounter
- T42.2X6DUnderdosing of succinimides and oxazolidinediones, subsequent encounter
- T42.2X6SUnderdosing of succinimides and oxazolidinediones, sequela
- T42.3X5AAdverse effect of barbiturates, initial encounter
- T42.3X5DAdverse effect of barbiturates, subsequent encounter
- T42.3X5SAdverse effect of barbiturates, sequela
- T42.3X6AUnderdosing of barbiturates, initial encounter
- T42.3X6DUnderdosing of barbiturates, subsequent encounter
- T42.3X6SUnderdosing of barbiturates, sequela
- T42.4X5AAdverse effect of benzodiazepines, initial encounter
- T42.4X5DAdverse effect of benzodiazepines, subsequent encounter
- T42.4X5SAdverse effect of benzodiazepines, sequela
- T42.4X6AUnderdosing of benzodiazepines, initial encounter
- T42.4X6DUnderdosing of benzodiazepines, subsequent encounter
- T42.4X6SUnderdosing of benzodiazepines, sequela
- T42.5X5AAdverse effect of mixed antiepileptics, initial encounter
- T42.5X5DAdverse effect of mixed antiepileptics, subsequent encounter
- T42.5X5SAdverse effect of mixed antiepileptics, sequela
- T42.5X6AUnderdosing of mixed antiepileptics, initial encounter
- T42.5X6DUnderdosing of mixed antiepileptics, subsequent encounter
- T42.5X6SUnderdosing of mixed antiepileptics, sequela
- T42.6X5AAdverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
- T42.6X5DAdverse effect of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
- T42.6X5SAdverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
- T42.6X6AUnderdosing of other antiepileptic and sedative-hypnotic drugs, initial encounter
- T42.6X6DUnderdosing of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
- T42.6X6SUnderdosing of other antiepileptic and sedative-hypnotic drugs, sequela
- T42.75XAAdverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
- T42.75XDAdverse effect of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter
- T42.75XSAdverse effect of unspecified antiepileptic and sedative-hypnotic drugs, sequela
- T42.76XAUnderdosing of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
- T42.76XDUnderdosing of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter
- T42.76XSUnderdosing of unspecified antiepileptic and sedative-hypnotic drugs, sequela
- T42.8X5AAdverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
- T42.8X5DAdverse effect of antiparkinsonism drugs and other central muscle-tone depressants, subsequent encounter
- T42.8X5SAdverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
- T42.8X6AUnderdosing of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
- T42.8X6DUnderdosing of antiparkinsonism drugs and other central muscle-tone depressants, subsequent encounter
- T42.8X6SUnderdosing of antiparkinsonism drugs and other central muscle-tone depressants, sequela
- T43.015AAdverse effect of tricyclic antidepressants, initial encounter
- T43.015DAdverse effect of tricyclic antidepressants, subsequent encounter
- T43.015SAdverse effect of tricyclic antidepressants, sequela
- T43.016AUnderdosing of tricyclic antidepressants, initial encounter
- T43.016DUnderdosing of tricyclic antidepressants, subsequent encounter
- T43.016SUnderdosing of tricyclic antidepressants, sequela
- T43.025AAdverse effect of tetracyclic antidepressants, initial encounter
- T43.025DAdverse effect of tetracyclic antidepressants, subsequent encounter
- T43.025SAdverse effect of tetracyclic antidepressants, sequela
- T43.026AUnderdosing of tetracyclic antidepressants, initial encounter
- T43.026DUnderdosing of tetracyclic antidepressants, subsequent encounter
- T43.026SUnderdosing of tetracyclic antidepressants, sequela
- T43.1X5AAdverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
- T43.1X5DAdverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter
- T43.1X5SAdverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
- T43.1X6AUnderdosing of monoamine-oxidase-inhibitor antidepressants, initial encounter
- T43.1X6DUnderdosing of monoamine-oxidase-inhibitor antidepressants, subsequent encounter
- T43.1X6SUnderdosing of monoamine-oxidase-inhibitor antidepressants, sequela
- T43.205AAdverse effect of unspecified antidepressants, initial encounter
- T43.205DAdverse effect of unspecified antidepressants, subsequent encounter
- T43.205SAdverse effect of unspecified antidepressants, sequela
- T43.206AUnderdosing of unspecified antidepressants, initial encounter
- T43.206DUnderdosing of unspecified antidepressants, subsequent encounter
- T43.206SUnderdosing of unspecified antidepressants, sequela
- T43.215AAdverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
- T43.215DAdverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
- T43.215SAdverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
- T43.216AUnderdosing of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
- T43.216DUnderdosing of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
- T43.216SUnderdosing of selective serotonin and norepinephrine reuptake inhibitors, sequela
- T43.225AAdverse effect of selective serotonin reuptake inhibitors, initial encounter
- T43.225DAdverse effect of selective serotonin reuptake inhibitors, subsequent encounter
- T43.225SAdverse effect of selective serotonin reuptake inhibitors, sequela
- T43.226AUnderdosing of selective serotonin reuptake inhibitors, initial encounter
- T43.226DUnderdosing of selective serotonin reuptake inhibitors, subsequent encounter
- T43.226SUnderdosing of selective serotonin reuptake inhibitors, sequela
- T43.295AAdverse effect of other antidepressants, initial encounter
- T43.295DAdverse effect of other antidepressants, subsequent encounter
- T43.295SAdverse effect of other antidepressants, sequela
- T43.296AUnderdosing of other antidepressants, initial encounter
- T43.296DUnderdosing of other antidepressants, subsequent encounter
- T43.296SUnderdosing of other antidepressants, sequela
- T43.3X5AAdverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
- T43.3X5DAdverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter
- T43.3X5SAdverse effect of phenothiazine antipsychotics and neuroleptics, sequela
- T43.3X6AUnderdosing of phenothiazine antipsychotics and neuroleptics, initial encounter
- T43.3X6DUnderdosing of phenothiazine antipsychotics and neuroleptics, subsequent encounter
- T43.3X6SUnderdosing of phenothiazine antipsychotics and neuroleptics, sequela
- T43.4X5AAdverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
- T43.4X5DAdverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter
- T43.4X5SAdverse effect of butyrophenone and thiothixene neuroleptics, sequela
- T43.4X6AUnderdosing of butyrophenone and thiothixene neuroleptics, initial encounter
- T43.4X6DUnderdosing of butyrophenone and thiothixene neuroleptics, subsequent encounter
- T43.4X6SUnderdosing of butyrophenone and thiothixene neuroleptics, sequela
- T43.505AAdverse effect of unspecified antipsychotics and neuroleptics, initial encounter
- T43.505DAdverse effect of unspecified antipsychotics and neuroleptics, subsequent encounter
- T43.505SAdverse effect of unspecified antipsychotics and neuroleptics, sequela
- T43.506AUnderdosing of unspecified antipsychotics and neuroleptics, initial encounter
- T43.506DUnderdosing of unspecified antipsychotics and neuroleptics, subsequent encounter
- T43.506SUnderdosing of unspecified antipsychotics and neuroleptics, sequela
- T43.595AAdverse effect of other antipsychotics and neuroleptics, initial encounter
- T43.595DAdverse effect of other antipsychotics and neuroleptics, subsequent encounter
- T43.595SAdverse effect of other antipsychotics and neuroleptics, sequela
- T43.596AUnderdosing of other antipsychotics and neuroleptics, initial encounter
- T43.596DUnderdosing of other antipsychotics and neuroleptics, subsequent encounter
- T43.596SUnderdosing of other antipsychotics and neuroleptics, sequela
- T43.605AAdverse effect of unspecified psychostimulants, initial encounter
- T43.605DAdverse effect of unspecified psychostimulants, subsequent encounter
- T43.605SAdverse effect of unspecified psychostimulants, sequela
- T43.606AUnderdosing of unspecified psychostimulants, initial encounter
- T43.606DUnderdosing of unspecified psychostimulants, subsequent encounter
- T43.606SUnderdosing of unspecified psychostimulants, sequela
- T43.615AAdverse effect of caffeine, initial encounter
- T43.615DAdverse effect of caffeine, subsequent encounter
- T43.615SAdverse effect of caffeine, sequela
- T43.616AUnderdosing of caffeine, initial encounter
- T43.616DUnderdosing of caffeine, subsequent encounter
- T43.616SUnderdosing of caffeine, sequela
- T43.625AAdverse effect of amphetamines, initial encounter
- T43.625DAdverse effect of amphetamines, subsequent encounter
- T43.625SAdverse effect of amphetamines, sequela
- T43.626AUnderdosing of amphetamines, initial encounter
- T43.626DUnderdosing of amphetamines, subsequent encounter
- T43.626SUnderdosing of amphetamines, sequela
- T43.635AAdverse effect of methylphenidate, initial encounter
- T43.635DAdverse effect of methylphenidate, subsequent encounter
- T43.635SAdverse effect of methylphenidate, sequela
- T43.636AUnderdosing of methylphenidate, initial encounter
- T43.636DUnderdosing of methylphenidate, subsequent encounter
- T43.636SUnderdosing of methylphenidate, sequela
- T43.655AAdverse effect of methamphetamines, initial encounter
- T43.655DAdverse effect of methamphetamines, subsequent encounter
- T43.655SAdverse effect of methamphetamines, sequela
- T43.656AUnderdosing of methamphetamines, initial encounter
- T43.656DUnderdosing of methamphetamines, subsequent encounter
- T43.656SUnderdosing of methamphetamines, sequela
- T43.695AAdverse effect of other psychostimulants, initial encounter
- T43.695DAdverse effect of other psychostimulants, subsequent encounter
- T43.695SAdverse effect of other psychostimulants, sequela
- T43.696AUnderdosing of other psychostimulants, initial encounter
- T43.696DUnderdosing of other psychostimulants, subsequent encounter
- T43.696SUnderdosing of other psychostimulants, sequela
- T43.8X5AAdverse effect of other psychotropic drugs, initial encounter
- T43.8X5DAdverse effect of other psychotropic drugs, subsequent encounter
- T43.8X5SAdverse effect of other psychotropic drugs, sequela
- T43.8X6AUnderdosing of other psychotropic drugs, initial encounter
- T43.8X6DUnderdosing of other psychotropic drugs, subsequent encounter
- T43.8X6SUnderdosing of other psychotropic drugs, sequela
- T43.95XAAdverse effect of unspecified psychotropic drug, initial encounter
- T43.95XDAdverse effect of unspecified psychotropic drug, subsequent encounter
- T43.95XSAdverse effect of unspecified psychotropic drug, sequela
- T43.96XAUnderdosing of unspecified psychotropic drug, initial encounter
- T43.96XDUnderdosing of unspecified psychotropic drug, subsequent encounter
- T43.96XSUnderdosing of unspecified psychotropic drug, sequela
- T44.0X5AAdverse effect of anticholinesterase agents, initial encounter
- T44.0X5DAdverse effect of anticholinesterase agents, subsequent encounter
- T44.0X5SAdverse effect of anticholinesterase agents, sequela
- T44.0X6AUnderdosing of anticholinesterase agents, initial encounter
- T44.0X6DUnderdosing of anticholinesterase agents, subsequent encounter
- T44.0X6SUnderdosing of anticholinesterase agents, sequela
- T44.1X5AAdverse effect of other parasympathomimetics [cholinergics], initial encounter
- T44.1X5DAdverse effect of other parasympathomimetics [cholinergics], subsequent encounter
- T44.1X5SAdverse effect of other parasympathomimetics [cholinergics], sequela
- T44.1X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter
- T44.1X6DUnderdosing of other parasympathomimetics [cholinergics], subsequent encounter
- T44.1X6SUnderdosing of other parasympathomimetics [cholinergics], sequela
- T44.2X5AAdverse effect of ganglionic blocking drugs, initial encounter
- T44.2X5DAdverse effect of ganglionic blocking drugs, subsequent encounter
- T44.2X5SAdverse effect of ganglionic blocking drugs, sequela
- T44.2X6AUnderdosing of ganglionic blocking drugs, initial encounter
- T44.2X6DUnderdosing of ganglionic blocking drugs, subsequent encounter
- T44.2X6SUnderdosing of ganglionic blocking drugs, sequela
- T44.3X5AAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
- T44.3X5DAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
- T44.3X5SAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
- T44.3X6AUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
- T44.3X6DUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
- T44.3X6SUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
- T44.4X5AAdverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
- T44.4X5DAdverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
- T44.4X5SAdverse effect of predominantly alpha-adrenoreceptor agonists, sequela
- T44.4X6AUnderdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
- T44.4X6DUnderdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter
- T44.4X6SUnderdosing of predominantly alpha-adrenoreceptor agonists, sequela
- T44.5X5AAdverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
- T44.5X5DAdverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
- T44.5X5SAdverse effect of predominantly beta-adrenoreceptor agonists, sequela
- T44.5X6AUnderdosing of predominantly beta-adrenoreceptor agonists, initial encounter
- T44.5X6DUnderdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter
- T44.5X6SUnderdosing of predominantly beta-adrenoreceptor agonists, sequela
- T44.6X5AAdverse effect of alpha-adrenoreceptor antagonists, initial encounter
- T44.6X5DAdverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
- T44.6X5SAdverse effect of alpha-adrenoreceptor antagonists, sequela
- T44.6X6AUnderdosing of alpha-adrenoreceptor antagonists, initial encounter
- T44.6X6DUnderdosing of alpha-adrenoreceptor antagonists, subsequent encounter
- T44.6X6SUnderdosing of alpha-adrenoreceptor antagonists, sequela
- T44.7X5AAdverse effect of beta-adrenoreceptor antagonists, initial encounter
- T44.7X5DAdverse effect of beta-adrenoreceptor antagonists, subsequent encounter
- T44.7X5SAdverse effect of beta-adrenoreceptor antagonists, sequela
- T44.7X6AUnderdosing of beta-adrenoreceptor antagonists, initial encounter
- T44.7X6DUnderdosing of beta-adrenoreceptor antagonists, subsequent encounter
- T44.7X6SUnderdosing of beta-adrenoreceptor antagonists, sequela
- T44.8X5AAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
- T44.8X5DAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
- T44.8X5SAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
- T44.8X6AUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
- T44.8X6DUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
- T44.8X6SUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela
- T44.905AAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
- T44.905DAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
- T44.905SAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
- T44.906AUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
- T44.906DUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
- T44.906SUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela
- T44.995AAdverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
- T44.995DAdverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
- T44.995SAdverse effect of other drug primarily affecting the autonomic nervous system, sequela
- T44.996AUnderdosing of other drug primarily affecting the autonomic nervous system, initial encounter
- T44.996DUnderdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter
- T44.996SUnderdosing of other drug primarily affecting the autonomic nervous system, sequela
- T45.0X5AAdverse effect of antiallergic and antiemetic drugs, initial encounter
- T45.0X5DAdverse effect of antiallergic and antiemetic drugs, subsequent encounter
- T45.0X5SAdverse effect of antiallergic and antiemetic drugs, sequela
- T45.0X6AUnderdosing of antiallergic and antiemetic drugs, initial encounter
- T45.0X6DUnderdosing of antiallergic and antiemetic drugs, subsequent encounter
- T45.0X6SUnderdosing of antiallergic and antiemetic drugs, sequela
- T45.1X5AAdverse effect of antineoplastic and immunosuppressive drugs, initial encounter
- T45.1X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
- T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs, sequela
- T45.1X6AUnderdosing of antineoplastic and immunosuppressive drugs, initial encounter
- T45.1X6DUnderdosing of antineoplastic and immunosuppressive drugs, subsequent encounter
- T45.1X6SUnderdosing of antineoplastic and immunosuppressive drugs, sequela
- T45.2X5AAdverse effect of vitamins, initial encounter
- T45.2X5DAdverse effect of vitamins, subsequent encounter
- T45.2X5SAdverse effect of vitamins, sequela
- T45.2X6AUnderdosing of vitamins, initial encounter
- T45.2X6DUnderdosing of vitamins, subsequent encounter
- T45.2X6SUnderdosing of vitamins, sequela
- T45.3X5AAdverse effect of enzymes, initial encounter
- T45.3X5DAdverse effect of enzymes, subsequent encounter
- T45.3X5SAdverse effect of enzymes, sequela
- T45.3X6AUnderdosing of enzymes, initial encounter
- T45.3X6DUnderdosing of enzymes, subsequent encounter
- T45.3X6SUnderdosing of enzymes, sequela
- T45.4X5AAdverse effect of iron and its compounds, initial encounter
- T45.4X5DAdverse effect of iron and its compounds, subsequent encounter
- T45.4X5SAdverse effect of iron and its compounds, sequela
- T45.4X6AUnderdosing of iron and its compounds, initial encounter
- T45.4X6DUnderdosing of iron and its compounds, subsequent encounter
- T45.4X6SUnderdosing of iron and its compounds, sequela
- T45.515AAdverse effect of anticoagulants, initial encounter
- T45.515DAdverse effect of anticoagulants, subsequent encounter
- T45.515SAdverse effect of anticoagulants, sequela
- T45.516AUnderdosing of anticoagulants, initial encounter
- T45.516DUnderdosing of anticoagulants, subsequent encounter
- T45.516SUnderdosing of anticoagulants, sequela
- T45.525AAdverse effect of antithrombotic drugs, initial encounter
- T45.525DAdverse effect of antithrombotic drugs, subsequent encounter
- T45.525SAdverse effect of antithrombotic drugs, sequela
- T45.526AUnderdosing of antithrombotic drugs, initial encounter
- T45.526DUnderdosing of antithrombotic drugs, subsequent encounter
- T45.526SUnderdosing of antithrombotic drugs, sequela
- T45.605AAdverse effect of unspecified fibrinolysis-affecting drugs, initial encounter
- T45.605DAdverse effect of unspecified fibrinolysis-affecting drugs, subsequent encounter
- T45.605SAdverse effect of unspecified fibrinolysis-affecting drugs, sequela
- T45.606AUnderdosing of unspecified fibrinolysis-affecting drugs, initial encounter
- T45.606DUnderdosing of unspecified fibrinolysis-affecting drugs, subsequent encounter
- T45.606SUnderdosing of unspecified fibrinolysis-affecting drugs, sequela
- T45.615AAdverse effect of thrombolytic drugs, initial encounter
- T45.615DAdverse effect of thrombolytic drugs, subsequent encounter
- T45.615SAdverse effect of thrombolytic drugs, sequela
- T45.616AUnderdosing of thrombolytic drugs, initial encounter
- T45.616DUnderdosing of thrombolytic drugs, subsequent encounter
- T45.616SUnderdosing of thrombolytic drugs, sequela
- T45.625AAdverse effect of hemostatic drug, initial encounter
- T45.625DAdverse effect of hemostatic drug, subsequent encounter
- T45.625SAdverse effect of hemostatic drug, sequela
- T45.626AUnderdosing of hemostatic drugs, initial encounter
- T45.626DUnderdosing of hemostatic drugs, subsequent encounter
- T45.626SUnderdosing of hemostatic drugs, sequela
- T45.695AAdverse effect of other fibrinolysis-affecting drugs, initial encounter
- T45.695DAdverse effect of other fibrinolysis-affecting drugs, subsequent encounter
- T45.695SAdverse effect of other fibrinolysis-affecting drugs, sequela
- T45.696AUnderdosing of other fibrinolysis-affecting drugs, initial encounter
- T45.696DUnderdosing of other fibrinolysis-affecting drugs, subsequent encounter
- T45.696SUnderdosing of other fibrinolysis-affecting drugs, sequela
- T45.7X5AAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
- T45.7X5DAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter
- T45.7X5SAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
- T45.7X6AUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, initial encounter
- T45.7X6DUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, subsequent encounter
- T45.7X6SUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, sequela
- T45.8X5AAdverse effect of other primarily systemic and hematological agents, initial encounter
- T45.8X5DAdverse effect of other primarily systemic and hematological agents, subsequent encounter
- T45.8X5SAdverse effect of other primarily systemic and hematological agents, sequela
- T45.8X6AUnderdosing of other primarily systemic and hematological agents, initial encounter
- T45.8X6DUnderdosing of other primarily systemic and hematological agents, subsequent encounter
- T45.8X6SUnderdosing of other primarily systemic and hematological agents, sequela
- T45.95XAAdverse effect of unspecified primarily systemic and hematological agent, initial encounter
- T45.95XDAdverse effect of unspecified primarily systemic and hematological agent, subsequent encounter
- T45.95XSAdverse effect of unspecified primarily systemic and hematological agent, sequela
- T45.96XAUnderdosing of unspecified primarily systemic and hematological agent, initial encounter
- T45.96XDUnderdosing of unspecified primarily systemic and hematological agent, subsequent encounter
- T45.96XSUnderdosing of unspecified primarily systemic and hematological agent, sequela
- T46.0X5AAdverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
- T46.0X5DAdverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
- T46.0X5SAdverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
- T46.0X6AUnderdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter
- T46.0X6DUnderdosing of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
- T46.0X6SUnderdosing of cardiac-stimulant glycosides and drugs of similar action, sequela
- T46.1X5AAdverse effect of calcium-channel blockers, initial encounter
- T46.1X5DAdverse effect of calcium-channel blockers, subsequent encounter
- T46.1X5SAdverse effect of calcium-channel blockers, sequela
- T46.1X6AUnderdosing of calcium-channel blockers, initial encounter
- T46.1X6DUnderdosing of calcium-channel blockers, subsequent encounter
- T46.1X6SUnderdosing of calcium-channel blockers, sequela
- T46.2X5AAdverse effect of other antidysrhythmic drugs, initial encounter
- T46.2X5DAdverse effect of other antidysrhythmic drugs, subsequent encounter
- T46.2X5SAdverse effect of other antidysrhythmic drugs, sequela
- T46.2X6AUnderdosing of other antidysrhythmic drugs, initial encounter
- T46.2X6DUnderdosing of other antidysrhythmic drugs, subsequent encounter
- T46.2X6SUnderdosing of other antidysrhythmic drugs, sequela
- T46.3X5AAdverse effect of coronary vasodilators, initial encounter
- T46.3X5DAdverse effect of coronary vasodilators, subsequent encounter
- T46.3X5SAdverse effect of coronary vasodilators, sequela
- T46.3X6AUnderdosing of coronary vasodilators, initial encounter
- T46.3X6DUnderdosing of coronary vasodilators, subsequent encounter
- T46.3X6SUnderdosing of coronary vasodilators, sequela
- T46.4X5AAdverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
- T46.4X5DAdverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
- T46.4X5SAdverse effect of angiotensin-converting-enzyme inhibitors, sequela
- T46.4X6AUnderdosing of angiotensin-converting-enzyme inhibitors, initial encounter
- T46.4X6DUnderdosing of angiotensin-converting-enzyme inhibitors, subsequent encounter
- T46.4X6SUnderdosing of angiotensin-converting-enzyme inhibitors, sequela
- T46.5X5AAdverse effect of other antihypertensive drugs, initial encounter
- T46.5X5DAdverse effect of other antihypertensive drugs, subsequent encounter
- T46.5X5SAdverse effect of other antihypertensive drugs, sequela
- T46.5X6AUnderdosing of other antihypertensive drugs, initial encounter
- T46.5X6DUnderdosing of other antihypertensive drugs, subsequent encounter
- T46.5X6SUnderdosing of other antihypertensive drugs, sequela
- T46.6X5AAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
- T46.6X5DAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
- T46.6X5SAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
- T46.6X6AUnderdosing of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
- T46.6X6DUnderdosing of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
- T46.6X6SUnderdosing of antihyperlipidemic and antiarteriosclerotic drugs, sequela
- T46.7X5AAdverse effect of peripheral vasodilators, initial encounter
- T46.7X5DAdverse effect of peripheral vasodilators, subsequent encounter
- T46.7X5SAdverse effect of peripheral vasodilators, sequela
- T46.7X6AUnderdosing of peripheral vasodilators, initial encounter
- T46.7X6DUnderdosing of peripheral vasodilators, subsequent encounter
- T46.7X6SUnderdosing of peripheral vasodilators, sequela
- T46.8X5AAdverse effect of antivaricose drugs, including sclerosing agents, initial encounter
- T46.8X5DAdverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
- T46.8X5SAdverse effect of antivaricose drugs, including sclerosing agents, sequela
- T46.8X6AUnderdosing of antivaricose drugs, including sclerosing agents, initial encounter
- T46.8X6DUnderdosing of antivaricose drugs, including sclerosing agents, subsequent encounter
- T46.8X6SUnderdosing of antivaricose drugs, including sclerosing agents, sequela
- T46.905AAdverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
- T46.905DAdverse effect of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
- T46.905SAdverse effect of unspecified agents primarily affecting the cardiovascular system, sequela
- T46.906AUnderdosing of unspecified agents primarily affecting the cardiovascular system, initial encounter
- T46.906DUnderdosing of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
- T46.906SUnderdosing of unspecified agents primarily affecting the cardiovascular system, sequela
- T46.995AAdverse effect of other agents primarily affecting the cardiovascular system, initial encounter
- T46.995DAdverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
- T46.995SAdverse effect of other agents primarily affecting the cardiovascular system, sequela
- T46.996AUnderdosing of other agents primarily affecting the cardiovascular system, initial encounter
- T46.996DUnderdosing of other agents primarily affecting the cardiovascular system, subsequent encounter
- T46.996SUnderdosing of other agents primarily affecting the cardiovascular system, sequela
- T47.0X5AAdverse effect of histamine H2-receptor blockers, initial encounter
- T47.0X5DAdverse effect of histamine H2-receptor blockers, subsequent encounter
- T47.0X5SAdverse effect of histamine H2-receptor blockers, sequela
- T47.0X6AUnderdosing of histamine H2-receptor blockers, initial encounter
- T47.0X6DUnderdosing of histamine H2-receptor blockers, subsequent encounter
- T47.0X6SUnderdosing of histamine H2-receptor blockers, sequela
- T47.1X5AAdverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
- T47.1X5DAdverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter
- T47.1X5SAdverse effect of other antacids and anti-gastric-secretion drugs, sequela
- T47.1X6AUnderdosing of other antacids and anti-gastric-secretion drugs, initial encounter
- T47.1X6DUnderdosing of other antacids and anti-gastric-secretion drugs, subsequent encounter
- T47.1X6SUnderdosing of other antacids and anti-gastric-secretion drugs, sequela
- T47.2X5AAdverse effect of stimulant laxatives, initial encounter
- T47.2X5DAdverse effect of stimulant laxatives, subsequent encounter
- T47.2X5SAdverse effect of stimulant laxatives, sequela
- T47.2X6AUnderdosing of stimulant laxatives, initial encounter
- T47.2X6DUnderdosing of stimulant laxatives, subsequent encounter
- T47.2X6SUnderdosing of stimulant laxatives, sequela
- T47.3X5AAdverse effect of saline and osmotic laxatives, initial encounter
- T47.3X5DAdverse effect of saline and osmotic laxatives, subsequent encounter
- T47.3X5SAdverse effect of saline and osmotic laxatives, sequela
- T47.3X6AUnderdosing of saline and osmotic laxatives, initial encounter
- T47.3X6DUnderdosing of saline and osmotic laxatives, subsequent encounter
- T47.3X6SUnderdosing of saline and osmotic laxatives, sequela
- T47.4X5AAdverse effect of other laxatives, initial encounter
- T47.4X5DAdverse effect of other laxatives, subsequent encounter
- T47.4X5SAdverse effect of other laxatives, sequela
- T47.4X6AUnderdosing of other laxatives, initial encounter
- T47.4X6DUnderdosing of other laxatives, subsequent encounter
- T47.4X6SUnderdosing of other laxatives, sequela
- T47.5X5AAdverse effect of digestants, initial encounter
- T47.5X5DAdverse effect of digestants, subsequent encounter
- T47.5X5SAdverse effect of digestants, sequela
- T47.5X6AUnderdosing of digestants, initial encounter
- T47.5X6DUnderdosing of digestants, subsequent encounter
- T47.5X6SUnderdosing of digestants, sequela
- T47.6X5AAdverse effect of antidiarrheal drugs, initial encounter
- T47.6X5DAdverse effect of antidiarrheal drugs, subsequent encounter
- T47.6X5SAdverse effect of antidiarrheal drugs, sequela
- T47.6X6AUnderdosing of antidiarrheal drugs, initial encounter
- T47.6X6DUnderdosing of antidiarrheal drugs, subsequent encounter
- T47.6X6SUnderdosing of antidiarrheal drugs, sequela
- T47.7X5AAdverse effect of emetics, initial encounter
- T47.7X5DAdverse effect of emetics, subsequent encounter
- T47.7X5SAdverse effect of emetics, sequela
- T47.7X6AUnderdosing of emetics, initial encounter
- T47.7X6DUnderdosing of emetics, subsequent encounter
- T47.7X6SUnderdosing of emetics, sequela
- T47.8X5AAdverse effect of other agents primarily affecting gastrointestinal system, initial encounter
- T47.8X5DAdverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter
- T47.8X5SAdverse effect of other agents primarily affecting gastrointestinal system, sequela
- T47.8X6AUnderdosing of other agents primarily affecting gastrointestinal system, initial encounter
- T47.8X6DUnderdosing of other agents primarily affecting gastrointestinal system, subsequent encounter
- T47.8X6SUnderdosing of other agents primarily affecting gastrointestinal system, sequela
- T47.95XAAdverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter
- T47.95XDAdverse effect of unspecified agents primarily affecting the gastrointestinal system, subsequent encounter
- T47.95XSAdverse effect of unspecified agents primarily affecting the gastrointestinal system, sequela
- T47.96XAUnderdosing of unspecified agents primarily affecting the gastrointestinal system, initial encounter
- T47.96XDUnderdosing of unspecified agents primarily affecting the gastrointestinal system, subsequent encounter
- T47.96XSUnderdosing of unspecified agents primarily affecting the gastrointestinal system, sequela
- T48.0X5AAdverse effect of oxytocic drugs, initial encounter
- T48.0X5DAdverse effect of oxytocic drugs, subsequent encounter
- T48.0X5SAdverse effect of oxytocic drugs, sequela
- T48.0X6AUnderdosing of oxytocic drugs, initial encounter
- T48.0X6DUnderdosing of oxytocic drugs, subsequent encounter
- T48.0X6SUnderdosing of oxytocic drugs, sequela
- T48.1X5AAdverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
- T48.1X5DAdverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
- T48.1X5SAdverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
- T48.1X6AUnderdosing of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
- T48.1X6DUnderdosing of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
- T48.1X6SUnderdosing of skeletal muscle relaxants [neuromuscular blocking agents], sequela
- T48.205AAdverse effect of unspecified drugs acting on muscles, initial encounter
- T48.205DAdverse effect of unspecified drugs acting on muscles, subsequent encounter
- T48.205SAdverse effect of unspecified drugs acting on muscles, sequela
- T48.206AUnderdosing of unspecified drugs acting on muscles, initial encounter
- T48.206DUnderdosing of unspecified drugs acting on muscles, subsequent encounter
- T48.206SUnderdosing of unspecified drugs acting on muscles, sequela
- T48.295AAdverse effect of other drugs acting on muscles, initial encounter
- T48.295DAdverse effect of other drugs acting on muscles, subsequent encounter
- T48.295SAdverse effect of other drugs acting on muscles, sequela
- T48.296AUnderdosing of other drugs acting on muscles, initial encounter
- T48.296DUnderdosing of other drugs acting on muscles, subsequent encounter
- T48.296SUnderdosing of other drugs acting on muscles, sequela
- T48.3X5AAdverse effect of antitussives, initial encounter
- T48.3X5DAdverse effect of antitussives, subsequent encounter
- T48.3X5SAdverse effect of antitussives, sequela
- T48.3X6AUnderdosing of antitussives, initial encounter
- T48.3X6DUnderdosing of antitussives, subsequent encounter
- T48.3X6SUnderdosing of antitussives, sequela
- T48.4X5AAdverse effect of expectorants, initial encounter
- T48.4X5DAdverse effect of expectorants, subsequent encounter
- T48.4X5SAdverse effect of expectorants, sequela
- T48.4X6AUnderdosing of expectorants, initial encounter
- T48.4X6DUnderdosing of expectorants, subsequent encounter
- T48.4X6SUnderdosing of expectorants, sequela
- T48.5X5AAdverse effect of other anti-common-cold drugs, initial encounter
- T48.5X5DAdverse effect of other anti-common-cold drugs, subsequent encounter
- T48.5X5SAdverse effect of other anti-common-cold drugs, sequela
- T48.5X6AUnderdosing of other anti-common-cold drugs, initial encounter
- T48.5X6DUnderdosing of other anti-common-cold drugs, subsequent encounter
- T48.5X6SUnderdosing of other anti-common-cold drugs, sequela
- T48.6X5AAdverse effect of antiasthmatics, initial encounter
- T48.6X5DAdverse effect of antiasthmatics, subsequent encounter
- T48.6X5SAdverse effect of antiasthmatics, sequela
- T48.6X6AUnderdosing of antiasthmatics, initial encounter
- T48.6X6DUnderdosing of antiasthmatics, subsequent encounter
- T48.6X6SUnderdosing of antiasthmatics, sequela
- T48.905AAdverse effect of unspecified agents primarily acting on the respiratory system, initial encounter
- T48.905DAdverse effect of unspecified agents primarily acting on the respiratory system, subsequent encounter
- T48.905SAdverse effect of unspecified agents primarily acting on the respiratory system, sequela
- T48.906AUnderdosing of unspecified agents primarily acting on the respiratory system, initial encounter
- T48.906DUnderdosing of unspecified agents primarily acting on the respiratory system, subsequent encounter
- T48.906SUnderdosing of unspecified agents primarily acting on the respiratory system, sequela
- T48.995AAdverse effect of other agents primarily acting on the respiratory system, initial encounter
- T48.995DAdverse effect of other agents primarily acting on the respiratory system, subsequent encounter
- T48.995SAdverse effect of other agents primarily acting on the respiratory system, sequela
- T48.996AUnderdosing of other agents primarily acting on the respiratory system, initial encounter
- T48.996DUnderdosing of other agents primarily acting on the respiratory system, subsequent encounter
- T48.996SUnderdosing of other agents primarily acting on the respiratory system, sequela
- T49.0X5AAdverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
- T49.0X5DAdverse effect of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter
- T49.0X5SAdverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
- T49.0X6AUnderdosing of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter
- T49.0X6DUnderdosing of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter
- T49.0X6SUnderdosing of local antifungal, anti-infective and anti-inflammatory drugs, sequela
- T49.1X5AAdverse effect of antipruritics, initial encounter
- T49.1X5DAdverse effect of antipruritics, subsequent encounter
- T49.1X5SAdverse effect of antipruritics, sequela
- T49.1X6AUnderdosing of antipruritics, initial encounter
- T49.1X6DUnderdosing of antipruritics, subsequent encounter
- T49.1X6SUnderdosing of antipruritics, sequela
- T49.2X5AAdverse effect of local astringents and local detergents, initial encounter
- T49.2X5DAdverse effect of local astringents and local detergents, subsequent encounter
- T49.2X5SAdverse effect of local astringents and local detergents, sequela
- T49.2X6AUnderdosing of local astringents and local detergents, initial encounter
- T49.2X6DUnderdosing of local astringents and local detergents, subsequent encounter
- T49.2X6SUnderdosing of local astringents and local detergents, sequela
- T49.3X5AAdverse effect of emollients, demulcents and protectants, initial encounter
- T49.3X5DAdverse effect of emollients, demulcents and protectants, subsequent encounter
- T49.3X5SAdverse effect of emollients, demulcents and protectants, sequela
- T49.3X6AUnderdosing of emollients, demulcents and protectants, initial encounter
- T49.3X6DUnderdosing of emollients, demulcents and protectants, subsequent encounter
- T49.3X6SUnderdosing of emollients, demulcents and protectants, sequela
- T49.4X5AAdverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
- T49.4X5DAdverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, subsequent encounter
- T49.4X5SAdverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
- T49.4X6AUnderdosing of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter
- T49.4X6DUnderdosing of keratolytics, keratoplastics, and other hair treatment drugs and preparations, subsequent encounter
- T49.4X6SUnderdosing of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
- T49.5X5AAdverse effect of ophthalmological drugs and preparations, initial encounter
- T49.5X5DAdverse effect of ophthalmological drugs and preparations, subsequent encounter
- T49.5X5SAdverse effect of ophthalmological drugs and preparations, sequela
- T49.5X6AUnderdosing of ophthalmological drugs and preparations, initial encounter
- T49.5X6DUnderdosing of ophthalmological drugs and preparations, subsequent encounter
- T49.5X6SUnderdosing of ophthalmological drugs and preparations, sequela
- T49.6X5AAdverse effect of otorhinolaryngological drugs and preparations, initial encounter
- T49.6X5DAdverse effect of otorhinolaryngological drugs and preparations, subsequent encounter
- T49.6X5SAdverse effect of otorhinolaryngological drugs and preparations, sequela
- T49.6X6AUnderdosing of otorhinolaryngological drugs and preparations, initial encounter
- T49.6X6DUnderdosing of otorhinolaryngological drugs and preparations, subsequent encounter
- T49.6X6SUnderdosing of otorhinolaryngological drugs and preparations, sequela
- T49.7X5AAdverse effect of dental drugs, topically applied, initial encounter
- T49.7X5DAdverse effect of dental drugs, topically applied, subsequent encounter
- T49.7X5SAdverse effect of dental drugs, topically applied, sequela
- T49.7X6AUnderdosing of dental drugs, topically applied, initial encounter
- T49.7X6DUnderdosing of dental drugs, topically applied, subsequent encounter
- T49.7X6SUnderdosing of dental drugs, topically applied, sequela
- T49.8X5AAdverse effect of other topical agents, initial encounter
- T49.8X5DAdverse effect of other topical agents, subsequent encounter
- T49.8X5SAdverse effect of other topical agents, sequela
- T49.8X6AUnderdosing of other topical agents, initial encounter
- T49.8X6DUnderdosing of other topical agents, subsequent encounter
- T49.8X6SUnderdosing of other topical agents, sequela
- T49.95XAAdverse effect of unspecified topical agent, initial encounter
- T49.95XDAdverse effect of unspecified topical agent, subsequent encounter
- T49.95XSAdverse effect of unspecified topical agent, sequela
- T49.96XAUnderdosing of unspecified topical agent, initial encounter
- T49.96XDUnderdosing of unspecified topical agent, subsequent encounter
- T49.96XSUnderdosing of unspecified topical agent, sequela
- T50.0X5AAdverse effect of mineralocorticoids and their antagonists, initial encounter
- T50.0X5DAdverse effect of mineralocorticoids and their antagonists, subsequent encounter
- T50.0X5SAdverse effect of mineralocorticoids and their antagonists, sequela
- T50.0X6AUnderdosing of mineralocorticoids and their antagonists, initial encounter
- T50.0X6DUnderdosing of mineralocorticoids and their antagonists, subsequent encounter
- T50.0X6SUnderdosing of mineralocorticoids and their antagonists, sequela
- T50.1X5AAdverse effect of loop [high-ceiling] diuretics, initial encounter
- T50.1X5DAdverse effect of loop [high-ceiling] diuretics, subsequent encounter
- T50.1X5SAdverse effect of loop [high-ceiling] diuretics, sequela
- T50.1X6AUnderdosing of loop [high-ceiling] diuretics, initial encounter
- T50.1X6DUnderdosing of loop [high-ceiling] diuretics, subsequent encounter
- T50.1X6SUnderdosing of loop [high-ceiling] diuretics, sequela
- T50.2X5AAdverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
- T50.2X5DAdverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter
- T50.2X5SAdverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
- T50.2X6AUnderdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
- T50.2X6DUnderdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter
- T50.2X6SUnderdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
- T50.3X5AAdverse effect of electrolytic, caloric and water-balance agents, initial encounter
- T50.3X5DAdverse effect of electrolytic, caloric and water-balance agents, subsequent encounter
- T50.3X5SAdverse effect of electrolytic, caloric and water-balance agents, sequela
- T50.3X6AUnderdosing of electrolytic, caloric and water-balance agents, initial encounter
- T50.3X6DUnderdosing of electrolytic, caloric and water-balance agents, subsequent encounter
- T50.3X6SUnderdosing of electrolytic, caloric and water-balance agents, sequela
- T50.4X5AAdverse effect of drugs affecting uric acid metabolism, initial encounter
- T50.4X5DAdverse effect of drugs affecting uric acid metabolism, subsequent encounter
- T50.4X5SAdverse effect of drugs affecting uric acid metabolism, sequela
- T50.4X6AUnderdosing of drugs affecting uric acid metabolism, initial encounter
- T50.4X6DUnderdosing of drugs affecting uric acid metabolism, subsequent encounter
- T50.4X6SUnderdosing of drugs affecting uric acid metabolism, sequela
- T50.5X5AAdverse effect of appetite depressants, initial encounter
- T50.5X5DAdverse effect of appetite depressants, subsequent encounter
- T50.5X5SAdverse effect of appetite depressants, sequela
- T50.5X6AUnderdosing of appetite depressants, initial encounter
- T50.5X6DUnderdosing of appetite depressants, subsequent encounter
- T50.5X6SUnderdosing of appetite depressants, sequela
- T50.6X5AAdverse effect of antidotes and chelating agents, initial encounter
- T50.6X5DAdverse effect of antidotes and chelating agents, subsequent encounter
- T50.6X5SAdverse effect of antidotes and chelating agents, sequela
- T50.6X6AUnderdosing of antidotes and chelating agents, initial encounter
- T50.6X6DUnderdosing of antidotes and chelating agents, subsequent encounter
- T50.6X6SUnderdosing of antidotes and chelating agents, sequela
- T50.7X5AAdverse effect of analeptics and opioid receptor antagonists, initial encounter
- T50.7X5DAdverse effect of analeptics and opioid receptor antagonists, subsequent encounter
- T50.7X5SAdverse effect of analeptics and opioid receptor antagonists, sequela
- T50.7X6AUnderdosing of analeptics and opioid receptor antagonists, initial encounter
- T50.7X6DUnderdosing of analeptics and opioid receptor antagonists, subsequent encounter
- T50.7X6SUnderdosing of analeptics and opioid receptor antagonists, sequela
- T50.8X5AAdverse effect of diagnostic agents, initial encounter
- T50.8X5DAdverse effect of diagnostic agents, subsequent encounter
- T50.8X5SAdverse effect of diagnostic agents, sequela
- T50.8X6AUnderdosing of diagnostic agents, initial encounter
- T50.8X6DUnderdosing of diagnostic agents, subsequent encounter
- T50.8X6SUnderdosing of diagnostic agents, sequela
- T50.915AAdverse effect of multiple unspecified drugs, medicaments and biological substances, initial encounter
- T50.915DAdverse effect of multiple unspecified drugs, medicaments and biological substances, subsequent encounter
- T50.915SAdverse effect of multiple unspecified drugs, medicaments and biological substances, sequela
- T50.916AUnderdosing of multiple unspecified drugs, medicaments and biological substances, initial encounter
- T50.916DUnderdosing of multiple unspecified drugs, medicaments and biological substances, subsequent encounter
- T50.916SUnderdosing of multiple unspecified drugs, medicaments and biological substances, sequela
- T50.A15AAdverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
- T50.A15DAdverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter
- T50.A15SAdverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
- T50.A16AUnderdosing of pertussis vaccine, including combinations with a pertussis component, initial encounter
- T50.A16DUnderdosing of pertussis vaccine, including combinations with a pertussis component, subsequent encounter
- T50.A16SUnderdosing of pertussis vaccine, including combinations with a pertussis component, sequela
- T50.A25AAdverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
- T50.A25DAdverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter
- T50.A25SAdverse effect of mixed bacterial vaccines without a pertussis component, sequela
- T50.A26AUnderdosing of mixed bacterial vaccines without a pertussis component, initial encounter
- T50.A26DUnderdosing of mixed bacterial vaccines without a pertussis component, subsequent encounter
- T50.A26SUnderdosing of mixed bacterial vaccines without a pertussis component, sequela
- T50.A95AAdverse effect of other bacterial vaccines, initial encounter
- T50.A95DAdverse effect of other bacterial vaccines, subsequent encounter
- T50.A95SAdverse effect of other bacterial vaccines, sequela
- T50.A96AUnderdosing of other bacterial vaccines, initial encounter
- T50.A96DUnderdosing of other bacterial vaccines, subsequent encounter
- T50.A96SUnderdosing of other bacterial vaccines, sequela
- T50.B15AAdverse effect of smallpox vaccines, initial encounter
- T50.B15DAdverse effect of smallpox vaccines, subsequent encounter
- T50.B15SAdverse effect of smallpox vaccines, sequela
- T50.B16AUnderdosing of smallpox vaccines, initial encounter
- T50.B16DUnderdosing of smallpox vaccines, subsequent encounter
- T50.B16SUnderdosing of smallpox vaccines, sequela
- T50.B95AAdverse effect of other viral vaccines, initial encounter
- T50.B95DAdverse effect of other viral vaccines, subsequent encounter
- T50.B95SAdverse effect of other viral vaccines, sequela
- T50.B96AUnderdosing of other viral vaccines, initial encounter
- T50.B96DUnderdosing of other viral vaccines, subsequent encounter
- T50.B96SUnderdosing of other viral vaccines, sequela
- T50.Z15AAdverse effect of immunoglobulin, initial encounter
- T50.Z15DAdverse effect of immunoglobulin, subsequent encounter
- T50.Z15SAdverse effect of immunoglobulin, sequela
- T50.Z16AUnderdosing of immunoglobulin, initial encounter
- T50.Z16DUnderdosing of immunoglobulin, subsequent encounter
- T50.Z16SUnderdosing of immunoglobulin, sequela
- T50.Z95AAdverse effect of other vaccines and biological substances, initial encounter
- T50.Z95DAdverse effect of other vaccines and biological substances, subsequent encounter
- T50.Z95SAdverse effect of other vaccines and biological substances, sequela
- T50.Z96AUnderdosing of other vaccines and biological substances, initial encounter
- T50.Z96DUnderdosing of other vaccines and biological substances, subsequent encounter
- T50.Z96SUnderdosing of other vaccines and biological substances, sequela
- T78.110AOther adverse food reactions due to milk and dairy products with tolerance to baked milk, initial encounter
- T78.110DOther adverse food reactions due to milk and dairy products with tolerance to baked milk, subsequent encounter
- T78.110SOther adverse food reactions due to milk and dairy products with tolerance to baked milk, sequela
- T78.111AOther adverse food reaction due to milk and dairy products with reactivity to baked milk, initial encounter
- T78.111DOther adverse food reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
- T78.111SOther adverse food reaction due to milk and dairy products with reactivity to baked milk, sequela
- T78.119AOther adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, initial encounter
- T78.119DOther adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, subsequent encounter
- T78.119SOther adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, sequela
- T78.120AOther adverse food reaction due to egg with tolerance to baked egg, initial encounter
- T78.120DOther adverse food reaction due to egg with tolerance to baked egg, subsequent encounter
- T78.120SOther adverse food reaction due to egg with tolerance to baked egg, sequela
- T78.121AOther adverse food reaction due to egg with reactivity to baked egg, initial encounter
- T78.121DOther adverse food reaction due to egg with reactivity to baked egg, subsequent encounter
- T78.121SOther adverse food reaction due to egg with reactivity to baked egg, sequela
- T78.129AOther adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, initial encounter
- T78.129DOther adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, subsequent encounter
- T78.129SOther adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, sequela
- T78.19XAOther adverse food reactions, not elsewhere classified, initial encounter
- T78.19XDOther adverse food reactions, not elsewhere classified, subsequent encounter
- T78.19XSOther adverse food reactions, not elsewhere classified, sequela
- T81.12XAPostprocedural septic shock, initial encounter
- T81.12XDPostprocedural septic shock, subsequent encounter
- T81.12XSPostprocedural septic shock, sequela